BURLINGAME, Calif.--(BUSINESS WIRE)--Aug. 10, 2016--
Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company
developing a proprietary therapeutic tissue treatment platform based on
Nano-Pulse Electro-Signaling (NPES™), announced today it will host an
investor conference call on September 7, 2016, at 4:30 p.m. EDT / 1:30
p.m. PDT. The company will highlight progress to date and provide an
overview of corporate strategies, financials, and future milestones.
"In this first investor call since our public offering, we look forward
to sharing ongoing progress and highlighting key milestones through 2016
and early 2017," stated Darrin Uecker, president and CEO of Pulse
Biosciences. “We are investing in the expansion of our internal team and
continued development of PulseTx™, our clinical system featuring the
world’s first tunable NPES treatment platform. Further, we are working
with key opinion leaders in key markets to identify therapeutic targets
and initiate pilot studies with PulseTx™. We join in their enthusiasm
about the potential and value of our unique treatment approach across
several significant markets, including immuno-oncology, dermatology and
veterinary medicine, as well as for the very large market for tissue
treatment applications.”
Conference Call Details
Pulse Biosciences’ Darrin Uecker, president and CEO, and other senior
executives will host the investor conference call on September 7, 2016,
at 4:30 p.m. EDT / 1:30 p.m. PDT. For both "listen-only" participants
and those who wish to take part in the question and answer portion of
the call, the telephone dial-in number is (844) 494-0190 (U.S.
toll-free) or (508) 637-5580 (international) with Conference ID
61405063. A link to the webcast will be made available on the Investor
Section of the company's website at www.pulsebiosciences.com
following the call.
About Pulse Biosciences
Pulse Biosciences (Nasdaq:PLSE) is a medical technology company
developing a therapeutic tissue treatment platform based on Nano-Pulse
Electro-Signaling (NPES™), a proprietary bioelectronics technology.
Published pre-clinical studies have shown that a single, brief exposure
of target tissue to NPES initiates a cascade of events within
cells and in the surrounding microenvironment that results in apoptosis
(cell death) and the priming of a durable adaptive immune response.
Pulse Biosciences is pursuing a variety of applications for NPES that
exploit its inherent advantages in lesion control and healing, including
immuno-oncology, dermatology, aesthetics, and veterinary medicine.
Clinical studies are being planned for the first commercial NPES system
designed to support a broad array of electrodes for use in superficial,
minimally-invasive, and open surgical procedures. More information is
available at www.pulsebiosciences.com.
Forward Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things, the
development of Pulse Biosciences’ business, statements relating to
future uses and markets for its NPES technology, and other future
events. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks, uncertainties,
changes in circumstances and other factors that are, in some cases,
beyond Pulse Biosciences’ control and could cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Factors that
could materially affect actual results can be found in Pulse
Biosciences’ most recent filings with the Securities and Exchange
Commission, including Pulse Biosciences’ most recent reports on Forms
S-1, as amended, and 10-Q, and include those listed under the caption
“Risk Factors.”
Pulse Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or circumstances in
the future, even if new information becomes available.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160810006095/en/
Source: Pulse Biosciences, Inc.
Pulse Biosciences, Inc.
Investors:
Brian Dow, Chief Financial
Officer
650-461-9050
IR@pulsebiosciences.com
or
Media:
Sam
Brown, Inc.
Hannah Hurdle, 818-456-4099
hannahhurdle@sambrown.com
